June 3 (Reuters) - Edwards Lifesciences ( EW ) on Monday

said it has agreed to sell its critical care products unit to

Becton Dickinson ( BDX ) in an all-cash transaction valued at

$4.2 billion.

With this agreement, California-based Edwards said it is no

longer pursuing the previously announced spin-off of the

critical care unit.

The medical device maker had

said in April

that it would spin off its critical care unit at the end of

2024 to concentrate on its larger heart devices business.

The transaction is expected to close by the end of 2024,

subject to the satisfaction or waiver of certain closing

conditions.